Imagion Biosystems is pleased to present the Company’s annual report for the year ending 31 December 2017.
Read the 2017 Annual Report to Shareholders.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)